ALKBH5‐Mediated m 6 A Modification of XBP1 Facilitates NSCLC Progression Through the IL‐6–JAK–STAT3 Pathway
Molecular Carcinogenesis · 2025
DOI: 10.1002/mc.23826 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Carcinogenesis, 2025. Verfasst von Hengxing Liang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Guilin Hospital of the Second Xiangya Hospital CSU, Guilin, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, X-Box Binding Protein 1, STAT3 Transcription Factor. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: The National Natural Science Foundation of China, The Natural Science Foundation of Hunan Province.
Abstract (Originalsprache)
The X‐box‐binding protein 1 (XBP1) is an important transcription factor during endoplasmic reticulum stress response, which was reported as an oncogene in non‐small cell lung cancer (NSCLC) tumorigenesis and development. However, the regulatory mechanism of XBP1 expression in NSCLC progression was less reported. N 6‐methyladenosine (m 6 A) RNA modification is an emerging epigenetic regulatory mechanism for gene expression. This study aimed to investigate the regulatory role of the m 6 A modification in XBP1 expression in NSCLC. We identified XBP1 as a downstream target of ALKBH5‐mediated m 6 A modification in A549 and PC9 cells. Knockdown of ALKBH5 increased the m 6 A modification and the stability of XBP1 mRNA, while overexpression of ALKBH5 had the opposite effect. Furthermore, IGF2BP3 was confirmed to be a reader of XBP1 m 6 A methylation and to enhance the stability of XBP1 mRNA. Additionally, IGF2BP3 knockdown significantly reversed the increase in XBP1 stability mediated by ALKBH5 depletion. In vivo and in vitro experiments demonstrated that ALKBH5/IGF2BP3 promotes the proliferation, migration, and invasion of NSCLC cells by upregulating XBP1 expression. In addition, we also showed that XBP1 promoted NSCLC cell proliferation, migration, and invasion by activating IL‐6–JAK–STAT3 signaling. Our research suggested that ALKBH5‐mediated m 6 A modification of XBP1 facilitates NSCLC progression through the IL‐6–JAK–STAT3 pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Guilin Hospital of the Second Xiangya Hospital CSU, Guilin, China.
- Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China.
- Institute of Foreign Languages, Central South University, Changsha, China.
- Xiangya Medical College, Central South University, Changsha, China.
- Hunan Science & Well Biotechnology Co., Ltd, Changsha, China.
Förderung
- The National Natural Science Foundation of China
- The Natural Science Foundation of Hunan Province
Zitieren
APA
Liang, H., Zhang, C., Hu, M., Hu, F., Wang, S., Wei, W., & Hu, W. (2025). ALKBH5‐Mediated m 6 A Modification of XBP1 Facilitates NSCLC Progression Through the IL‐6–JAK–STAT3 Pathway. Molecular Carcinogenesis. https://doi.org/10.1002/mc.23826
Vancouver
Liang H, Zhang C, Hu M, Hu F, Wang S, Wei W, et al. ALKBH5‐Mediated m 6 A Modification of XBP1 Facilitates NSCLC Progression Through the IL‐6–JAK–STAT3 Pathway. Molecular Carcinogenesis. 2025. doi:10.1002/mc.23826
BibTeX
@article{Liang2025,
author = {Liang, Hengxing and Zhang, Chunmin and Hu, Minxin and Hu, Fang and Wang, Saihui and Wei, Wei and Hu, Wen},
title = {ALKBH5‐Mediated m 6 A Modification of XBP1 Facilitates NSCLC Progression Through the IL‐6–JAK–STAT3 Pathway},
journal = {Molecular Carcinogenesis},
year = {2025},
doi = {10.1002/mc.23826}
}
EUVIMED